Fairfield Financial Advisors LTD Buys Shares of 14,210 Eli Lilly and Company (NYSE:LLY)

Fairfield Financial Advisors LTD acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 14,210 shares of the company’s stock, valued at approximately $12,866,000. Eli Lilly and Company makes up about 4.5% of Fairfield Financial Advisors LTD’s investment portfolio, making the stock its 7th largest position.

Other institutional investors also recently bought and sold shares of the company. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $29,000. Core Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth $37,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LLY. Truist Financial reissued a “buy” rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 9th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Down 1.2 %

Shares of LLY opened at $923.71 on Monday. The company has a market capitalization of $877.92 billion, a price-to-earnings ratio of 136.04, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The stock’s 50-day moving average price is $897.12 and its 200-day moving average price is $833.89. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 451,900 shares of company stock worth $418,732,178 over the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.